Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Vedolizumab in Ulcerative Colitis and Crohn's Disease
2008-002784-14Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vedolizumab in autoimmune colitis and Crohn's disease, sponsored by Millennium Pharmaceuticals. Primary endpoints: Primary safety outcomes, Resource utilization and 2 more. Started Oct 2008; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2008-002784-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002784-14.